However, among all genes analyzed, we found that KRAS is the top-ranked gene whose mutation status was significantly associated with predicted tumor sensitivity to trametinib for the largest number of tumor types (seven of the 31) (Fig. 4b). The gene discussed is KRAS; the disease is neoplasm.